• Publications
  • Influence
Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.
In a 3-year, randomized, controlled, open-label phase III trial enrolling 3707 adults aged > or = 60 years we evaluated whether the immunogenicity of an intradermal trivalent inactivated seasonalExpand
  • 152
  • 10
Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: Randomized, controlled, Phase III trial
Background: Vaccination is the most effective way of reducing the large health and economic burden of influenza, yet vaccination coverage remains low, particularly among non-elderly adults.Expand
  • 62
  • 2
Intradermal Influenza Vaccine Elicits Superior Immunogenicity in Adults Aged ≥60 Years: A Randomized Controlled Phase 3 Trial
28% (1360/4890); 45% (520/1154) in meningitis and 22% (840/3736) in other IPD cases (p < 0.001). Of patients tested for HIV, HIV-seroprevalence was 512/664 (77%) amongst meningitis cases andExpand
  • 1